Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients

Transplantation. 2004 Dec 27;78(12):1765-73. doi: 10.1097/01.tp.0000142619.01510.a5.

Abstract

Background: Cytomegalovirus (CMV) D+/R- solid-organ transplant (SOT) recipients carry increased risk of developing CMV disease; however, other risk factors in these patients have not been delineated.

Methods: We examined 20 demographic and clinical variables for their association with the development of CMV disease, as defined by an independent endpoint committee (IEC) and also by the investigator (investigator treated [IT]), or CMV viremia within 12 months of transplant in D+/R- transplant recipients who received prophylaxis with valganciclovir or oral ganciclovir for 100 days.

Results: Recipients with low creatinine clearance (Ccr,<40 mL/min) at screening had a significantly increased hazard of developing IEC-defined CMV disease (hazards ratio [HR]=4.28, confidence interval [CI] 1.69, 10.83). Females were twice as likely (HR=2.19, CI .21, 3.99) to develop IEC-defined CMV disease than males. These variables were associated with an increased risk of IEC-defined CMV disease in time-dependent models. Recipients with blood group A were also more likely to develop IEC-defined CMV disease than those with group O (HR=2.36 CI 1.24, 4.51) in the logistic regression model only. Prophylactic drug, organ type, recipient age, rejection episodes, and maintenance immunosuppression regimen were not associated with IEC-defined CMV disease. Female sex was the only variable associated with the development of CMV viremia (odds ratio [OR]=1.65; CI 1.03, 2.65) and IT CMV disease (OR=1.78; CI 1.08, 2.93).

Conclusions: Low Ccr at screening and blood type A are risk factors for IEC-defined CMV disease, and female sex was a risk factor for IEC- and IT-defined CMV disease and viremia in high-risk SOT recipients. These variables should perhaps be considered when optimizing treatment.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ABO Blood-Group System
  • Adolescent
  • Adult
  • Antiviral Agents / therapeutic use*
  • Creatinine / metabolism
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / etiology*
  • Cytomegalovirus Infections / prevention & control*
  • Double-Blind Method
  • Female
  • Ganciclovir / analogs & derivatives*
  • Ganciclovir / therapeutic use
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Organ Transplantation / adverse effects*
  • Proportional Hazards Models
  • Risk Factors
  • Sex Factors
  • Time Factors
  • Valganciclovir
  • Viremia / etiology*
  • Viremia / prevention & control*

Substances

  • ABO Blood-Group System
  • Antiviral Agents
  • Creatinine
  • Valganciclovir
  • Ganciclovir